Kodiak Sciences (KOD) Research & Development (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Research & Development came in at $48.5 million in Q1 2026, up 11.23% YoY from $43.6 million in Q1 2025, and up 6.71% on a QoQ basis from $45.5 million in Q4 2025.
Kodiak Sciences (KOD) Research & Development (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Research & Development data on file, last reported at $48.5 million in Q1 2026.
- Quarterly Research & Development rose 11.23% year-over-year to $48.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $187.3 million (up 33.95% YoY) and the FY2025 annual result came in at $182.4 million, up 44.63% from the prior year.
- Research & Development advanced to $48.5 million in Q1 2026, from $45.5 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $76.2 million in Q1 2022 to a low of $29.9 million in Q1 2024.
- A 5-year average of $48.9 million and a median of $46.6 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 88.85% — and 2024, when it sank 51.44%.
- Tracing KOD's Research & Development over 5 years: stood at $56.0 million in 2022, then slipped by 16.73% to $46.6 million in 2023, then tumbled by 31.86% to $31.8 million in 2024, then surged by 43.19% to $45.5 million in 2025, then climbed by 6.71% to $48.5 million in 2026.
- The last three Research & Development figures came in at $48.5 million (Q1 2026), $45.5 million (Q4 2025), and $50.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Kodiak Sciences | 2.60 Bn | 2.60 Bn | - | 56.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.08 Mn |
| Mar 31, 2026 | 48.55 Mn |
| Dec 31, 2025 | 45.49 Mn |
| Sep 30, 2025 | 50.48 Mn |
| Jun 30, 2025 | 42.76 Mn |
| Mar 31, 2025 | 43.64 Mn |
| Dec 31, 2024 | 31.77 Mn |
| Sep 30, 2024 | 31.88 Mn |
| Jun 30, 2024 | 32.51 Mn |
| Mar 31, 2024 | 29.93 Mn |
| Dec 31, 2023 | 46.63 Mn |
| Sep 30, 2023 | 36.19 Mn |
| Jun 30, 2023 | 66.96 Mn |
| Mar 31, 2023 | 56.52 Mn |
| Dec 31, 2022 | 55.99 Mn |
| Sep 30, 2022 | 61.68 Mn |
| Jun 30, 2022 | 73.74 Mn |
| Mar 31, 2022 | 76.18 Mn |
| Dec 31, 2021 | 75.60 Mn |
| Sep 30, 2021 | 56.00 Mn |